These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 28800074

  • 21. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC.
    J Clin Oncol; 2012 May 01; 30(13):1505-12. PubMed ID: 22412142
    [Abstract] [Full Text] [Related]

  • 22. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F.
    Int J Cancer; 2014 May 01; 134(9):2146-55. PubMed ID: 24136682
    [Abstract] [Full Text] [Related]

  • 29. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F.
    Clin Cancer Res; 2013 Dec 15; 19(24):6751-65. PubMed ID: 24122793
    [Abstract] [Full Text] [Related]

  • 30. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y, Guo M, Wei Y, Yu S, Li H, Wang Y, Xu X, Cui Y, Tian J, Liang L, Peng K, Liu T.
    Oncotarget; 2016 Dec 06; 7(49):80888-80900. PubMed ID: 27825133
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D, Huang X, Cai J, Guo S, Qian W, Wery JP, Li QX.
    Oncotarget; 2015 Dec 01; 6(38):40815-21. PubMed ID: 26512781
    [Abstract] [Full Text] [Related]

  • 35. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
    Wang G, Huang Y, Wu Z, Zhao C, Cong H, Ju S, Wang X.
    Biosci Rep; 2019 Mar 29; 39(3):. PubMed ID: 30674639
    [Abstract] [Full Text] [Related]

  • 36. Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.
    Hu Y, Dong XZ, Liu X, Liu P, Chen YB.
    Mol Pharm; 2016 Feb 01; 13(2):689-97. PubMed ID: 26685983
    [Abstract] [Full Text] [Related]

  • 37. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA, Trusolino L, Velculescu VE.
    Nature; 2015 Oct 08; 526(7572):263-7. PubMed ID: 26416732
    [Abstract] [Full Text] [Related]

  • 38. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T.
    Cancer Res; 2011 Mar 01; 71(5):1520-5. PubMed ID: 21193546
    [Abstract] [Full Text] [Related]

  • 39. Active Compound of Pharbitis Semen (Pharbitis nil Seeds) Suppressed KRAS-Driven Colorectal Cancer and Restored Muscle Cell Function during Cancer Progression.
    Song J, Seo H, Kim MR, Lee SJ, Ahn S, Song M.
    Molecules; 2020 Jun 22; 25(12):. PubMed ID: 32580297
    [Abstract] [Full Text] [Related]

  • 40. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
    Park JJ, Yi JY, Jin YB, Lee YJ, Lee JS, Lee YS, Ko YG, Lee M.
    Biochem Pharmacol; 2012 Apr 01; 83(7):849-57. PubMed ID: 22266356
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.